

## Contribution of DNA polymerase eta to immunoglobulin gene hypermutation in the mouse.

Frédéric Delbos, Annie de Smet, Ahmad Faili, Said Aoufouchi, Jean-Claude Weill, Claude-Agnès Reynaud

► **To cite this version:**

Frédéric Delbos, Annie de Smet, Ahmad Faili, Said Aoufouchi, Jean-Claude Weill, et al.. Contribution of DNA polymerase eta to immunoglobulin gene hypermutation in the mouse.. The Journal of Experimental Medicine, The Rockefeller University Press, 2005, 201 (8), pp.1191-6. 10.1084/jem.20050292 . inserm-00310380

**HAL Id: inserm-00310380**

**<https://www.hal.inserm.fr/inserm-00310380>**

Submitted on 8 Aug 2008

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

# Contribution of DNA polymerase $\eta$ to immunoglobulin gene hypermutation in the mouse

Frédéric Delbos, Annie De Smet, Ahmad Faili, Said Aoufouchi, Jean-Claude Weill, and Claude-Agnès Reynaud

Institut National de la Santé et de la Recherche Médicale U373, Faculté de Médecine Necker-Enfants Malades-Université Paris V, 75730 Paris Cedex 15, France

**The mutation pattern of immunoglobulin genes was studied in mice deficient for DNA polymerase  $\eta$ , a translesional polymerase whose inactivation is responsible for the xeroderma pigmentosum variant (XP-V) syndrome in humans. Mutations show an 85% G/C biased pattern, similar to that reported for XP-V patients. Breeding these mice with animals harboring the stop codon mutation of the 129/Olain background in their DNA polymerase  $\iota$  gene did not alter this pattern further. Although this G/C biased mutation profile resembles that of mice deficient in the MSH2 or MSH6 components of the mismatch repair complex, the residual A/T mutagenesis of pol $\eta$ -deficient mice differs markedly. This suggests that, in the absence of pol $\eta$ , the MSH2–MSH6 complex is able to recruit another DNA polymerase that is more accurate at copying A/T bases, possibly pol $\kappa$ , to assume its function in hypermutation.**

## CORRESPONDENCE

Claude-Agnès Reynaud:  
reynaud@necker.fr  
OR  
Jean-Claude Weill:  
weill@necker.fr

Somatic hypermutation of immunoglobulin genes is initiated by activation-induced cytidine deaminase (AID; reference 1). Most experimental evidences suggest that AID initiates this process by deaminating cytidines into uracils in DNA (2). Accordingly, overexpression of AID in fibroblasts is sufficient to induce a G/C-targeted mutagenesis on a highly transcribed reporter gene (3). This mutagenesis is supposed to occur by saturation of the repair capacity of the cell, generating transition mutations by replication over the uracils created by deamination. Transversion mutations are likely generated by one or several translesional polymerases that ensure the replication bypass of abasic sites that failed to be corrected by the classical base excision repair pathway after excision of uracils by uracil glycosylases.


In contrast with this “passive” mutagenic process, hypermutation in activated B cells generates mutations at all four bases at the Ig locus (4). This mutagenesis is entirely dependent on the initial handling of the lesion by only two pathways, one dependent on the uracil glycosylase UNG, the other one upon a

subset of the mismatch repair complex, its DNA binding moiety MSH2–MSH6, together with exonuclease 1 (Exo1; references 5–13). The UNG pathway appears necessary for generating most transversion mutations at G/C bases, whereas the MSH2–MSH6 pathway is required for a large part of the mutagenesis at A/T positions.

Translesional DNA polymerases are specific enzymes, recruited at replication forks stalled in front of noninstructional DNA lesions, and able to bypass them with various specificities and efficiencies (for review see reference 14). Moreover, based on in vitro assays, many of them are inherently error prone when copying undamaged DNA, again with various intrinsic misincorporation specificities, which made them prime candidates for the Ig gene mutational process, and several experimental data have indeed documented their involvement. The Ig gene mutation profile of xeroderma pigmentosum variant (XP-V) patients, deficient in DNA polymerase  $\eta$  (15), has suggested that this enzyme is a major contributor of the MSH2–MSH6 driven A/T mutagenesis (16–18). The DNA polymerase  $\iota$ , which colocalizes with pol $\eta$  at replication foci (19), has been implied in the Ig gene mutagenesis induced in a Burkitt’s lymphoma cell line (20). However, inactivation

J.-C. Weill and C.-A. Reynaud share senior authorship for this work.

The online version of this article contains supplemental material.



**Figure 1. Disruption of the mouse *Polh* gene.** (A) Scheme of the mouse *Polh* gene encoding DNA polymerase  $\eta$ . (Closed boxes) coding exons; (open boxes) noncoding regions. (B) Scheme of the gene targeting strategy. Homologous recombination of the gene-targeting construct results in the introduction of loxP sites on both sides of exon 4. (C) Screening of mouse genotypes: deletion of exon 4 is monitored by a PCR around this exon, using primers shown in B. (D) *Polh* gene expression in control and gene-targeted mice: amplification of *polh* transcripts is performed using primers in exons 2 and 6, on twofold consecutive dilutions of RT products from total spleen RNA. The amplified product in *polh*<sup>-/-</sup> animals corresponds to the splicing of exons 3–5, which generates an out-of-frame sequence.

of this enzyme in the mouse, by a stop codon present as a natural mutation of various 129 substrains, failed to show any phenotype on hypermutation (21). DNA polymerase  $\zeta$  is proposed to contribute to the overall quantitative efficiency of the process, but not to any specific pathway (22, 23).

To look for possible differences in the various DNA polymerases involved between mouse and humans, we inactivated *polh* in the mouse, and analyzed the Ig mutation pattern in the context of the *polu* mutation of the 129/Ola strain. This analysis confirms the phenotype observed for *polh* deficiency in humans, which is not altered further in the presence of the *polu* mutation of the 129 background.

## RESULTS AND DISCUSSION

Inactivation of the mouse *Polh* gene was performed by a conditional knock-out strategy that introduces loxP sites flanking exon 4, an exon containing the DE polymerase motifs conserved in all Y-family polymerases and indispensable for *polh* catalytic function (Fig. 1 and references 15, 24). This strategy was designed with the aim of crossing the animals obtained with mice harboring other DNA repair defects, allowing the follow-up of the B cell lineage in case of lethality of their combined deficiencies. Deletion of exon 4 was performed here in the targeted embryonic stem (ES) cell clone, leaving in place a single loxP site and, therefore, minimizing disturbance around the gene. The *Xpo5* gene, encoding exportin-5 involved in the nuclear export of microRNAs, indeed initiates 200 bp upstream from the first *Polh* exon in opposite transcriptional orientation; affecting expression of this gene is, therefore, likely to result in an early embryonic lethal phenotype (25).


The heterozygotes obtained by breeding chimeras with C57Bl/6 mice were crossed together and screened for the presence of the stop codon mutation born by the *Poli* gene from the 129/Ola genetic background of the ES cells. Wild-type, homozygous *polh*-deficient, and double *polh*-*polu* mutant mice were selected for analysis. Deletion of exon 4 of *polh* resulted at the transcriptional level in the direct splicing of exons 3–5, an out-of-frame junction that introduces a stop codon 11 amino acids downstream in exon 5 and generates a truncated *polh* protein of 102 amino acids (Fig. 1 D). Apart from deletion of exon 4, such a truncated protein would lack domains involved in nuclear localization and repair foci formation (19).

Wild-type, *polh*-deficient, and double *polh*-*polu* mutant mice were analyzed for the mutation pattern of their Ig locus. Different types of sequences were analyzed: intronic sequences flanking rearranged J<sub>H</sub>4 sequences (“J<sub>H</sub>4 intronic sequences”) and a 560-bp region upstream from the repeats of the S $\mu$  core sequence (hereafter referred to as “pre-switch”), both from Peyer’s patch PNA<sup>high</sup> B cells (Table I).

No B cell anomalies were observed in either type of polymerase-deficient animals. Ig sequences from *polh*<sup>-/-</sup> PNA<sup>high</sup> B cells displayed the same specific pattern as those

**Table I.** Somatic mutations in J<sub>H</sub>4 intronic sequences and S $\mu$  core upstream sequences from normal and mutant mice

	J <sub>H</sub> 4 intronic sequence (490 bp)			S $\mu$ core upstream sequence (560 bp)		
	Controls	<i>Polh</i> <sup>-/-</sup>	<i>Polh</i> <sup>-/-</sup> × <i>polu</i> <sup>-/-</sup>	Controls	<i>Polh</i> <sup>-/-</sup>	<i>Polh</i> <sup>-/-</sup> × <i>polu</i> <sup>-/-</sup>
Number of sequences	21	71	53	96	122	127
Total length sequenced (bp)	10,290	34,790	25,970	53,760	66,320	71,120
Unmutated sequences (%)	14	17	25	42	46	57
Total number of mutations	124	241	129	147	160	122
Number of deletions and insertions	2	4	0	4	3	2
Mutation frequency per total sequences (per 100 bp)	1.2	0.7	0.5	0.3	0.2	0.2
Mutation frequency per mutated sequences (per 100 bp)	1.4	0.8	0.7	0.5	0.4	0.4



**Figure 2. Distribution of mutations in the V<sub>H</sub>DJ<sub>H4</sub> flanking sequence ("J<sub>H4</sub> intronic region") of Peyer's patches PNA<sup>high</sup> B cells from *polη*<sup>-/-</sup> and *polη*<sup>-/-</sup>*polu*<sup>-/-</sup> deficient mice. (A) Pattern of nucleotide substitution in control mice (two animals), *polη*<sup>-/-</sup> deficient mice (three animals), *polη*<sup>-/-</sup> and *polu*<sup>-/-</sup> deficient mice (two animals), and from all mutant animals together. Data are given as percent substitution after correction for base composition (490 bp starting from the exon/intron border: A, 26.3%; C, 14.9%; G, 27.4%; T, 31.4%). (B) Accumulation of mutations in individual J<sub>H4</sub> intronic sequences. The distribution of sequences harboring a given number of mutations relative to the total number of mutated sequences is represented for the three mouse genotypes.**

obtained from memory B cells of XP-V patients; i.e., a marked reduction of mutations at A/T base pairs: 86.1% mutations at G/C base pairs for the J<sub>H4</sub> intron and 88.6% for the pre-switch sequence (vs. 89.3 and 89.8% for the corresponding Ig gene sequences in XP-V patients; Figs. 2 and 3, Table II, and reference 17). Mutation frequencies were somewhat lower for *polη*<sup>-/-</sup> deficient animals compared with wild type when J<sub>H4</sub> intronic sequences are considered, but similar for the pre-switch sequences. Such a quantitative dissociation has been described for MSH6- and for UNG/MSH2-deficient animals (5, 13).

We next compared the mutation profile of mice harboring both *polη* and *polu* inactivation. These profiles appear extremely similar, either in their distribution along the se-

quence (shown for the pre-switch sequence in Fig. 3 C), or in their base substitution characteristics (Figs. 2 A and 3 A). The lack of phenotype of *polu*-deficient mice on Ig gene hypermutation is, therefore, not due to a compensatory role of *polη* in this specific strain.

All further analyses were, therefore, performed on pooled data from both types of mutant mice, allowing us to compare larger databases (366 mutations for the J<sub>H4</sub> intron and 277 for the pre-switch sequence). The targeting was slightly more pronounced for C than for G, in particular for the pre-switch sequence. Such an increase has been described in switch junctions from XP-V patients (18). However, among the three types of sequences that we have analyzed in similar patients, we could not observe this bias in either switch junctions or J<sub>H4</sub> introns, the specific increase in C mutations being only significant in pre-switch sequences from XP-V individuals (17). The general relevance of this observation is, therefore, difficult to assess at this stage. Moreover, among G/C mutations, no difference from wild type is noticeable in the relative proportion of transitions and transversions (Table II).

MSH2 deficiency, together with defects in MSH6 and Exo1, results in a similar bias toward G/C mutagenesis (7–13). We, therefore, wanted to compare the mutation pattern in the J<sub>H4</sub> intronic sequence between *Msh2*<sup>-/-</sup> and *Polh*<sup>-/-</sup> animals. This pattern was established using data from both MSH2- and Exo1-deficient animals, as well as MSH2-ATPase mutant mice (326 mutations), taking into account only data obtained using Pfu polymerase, to exclude any contribution of less accurate enzymes whose intrinsic error spectrum might specifically impinge on the A/T pattern. At G/C base pairs, these mutant mice show a strong bias toward transi-

**Table II.** Pattern of nucleotide changes in J<sub>H4</sub> intronic sequences of normal, *polη*<sup>-/-</sup>, and MSH2-deficient mice

Mouse	GC:AT	Transitions: transversions	Within G/C			Within A/T		
			Trans.	Transv.	Trans.	Transv.	Transv.	
			G/A C/T	G/T C/A	G/C	A/G T/C	A/T T/A	A/C T/G
Controls 1 <sup>a</sup>	44.3:55.7	53.7:46.3	61.4	18.5	20.1	47.6	26.2	26.2
Controls 1 <sup>b</sup>	49.9:50.1	53.3:46.7	54.5	16.8	28.7	52.1	25.9	22.0
<i>Polη</i> <sup>-/-c</sup>	<b>85.5:14.5</b>	51.3:48.7	57.1	12.7	30.2	<b>17.2</b>	26.2	<b>56.2</b>
<i>Msh2</i> <sup>-/-d</sup>	<b>87.0:13.0</b>	<b>71.2:28.8</b>	<b>74.0</b>	14.0	12.0	52.7	25.7	21.6
Human								
Controls 1 <sup>e</sup>	46.0:54.0	51.2:48.8	55.4	16.5	28.1	47.6	25.0	27.4
XP-V <sup>e</sup>	<b>89.3:10.7</b>	46.6:53.4	51.1	17.1	31.8	<b>9.4</b>	36.4	<b>54.2</b>

Values in bold represent significant differences from controls discussed in the text.

<sup>a</sup>This study (122 mutations).

<sup>b</sup>From a larger sample (334 mutations; reference 36).

<sup>c</sup>This study, data from all deficient mice together (366 mutations).

<sup>d</sup>Data from mice deficient in the MSH2-dependent pathway (*Msh2*<sup>-/-</sup>, *Exo1*<sup>-/-</sup>, *Msh2*<sup>26674A</sup>) were pooled (326 mutations obtained by Pfu polymerase; references 8, 11, 12).

<sup>e</sup>From ref. 17 (168 mutations).



Pol $\mu$  is another enzyme with such a transversion bias (29). However, contrary to pol $\eta$  and pol $\kappa$ , its preferred misincorporation is at copying A, and not T. It is therefore unlikely, in the mouse at least, that pol $\mu$  could generate the A over T bias of mutations in J<sub>H</sub>4 sequences, present in control mice and conserved in pol $\eta$ -deficient animals.

UNG and MSH2–MSH6 are the only two repair pathways handling uracils generated by AID during Ig gene hypermutation. The model of Neuberger et al. (5) posits that G/C mutations are introduced by replication over the uracils or the abasic sites generated by uracil glycosylase, both events occurring on the DNA strand opposed to the lesion and without repair. Replication over the abasic site would involve translesional DNA polymerases in their “classical” role of damage bypass. Effectively, in the AID-dependent mutations observed in the chicken cell line DT40 that are almost entirely restricted to G/C bases, Rev1 has been proposed to be the major enzyme involved (30). As the mutation pattern of DT40 is more biased toward G to C and C to G transversions (the hallmark of Rev1) than it is in the mouse, it is so far unclear how many translesional polymerases are involved in the G/C mutation pattern in mouse (and human) B cells. Mutations at A/T bases are more difficult to explain on a strict replication mode within this model.

In another scenario, the MSH2–MSH6 complex would recruit pol $\eta$  for an error-prone repair of the lesion (i.e., on the same DNA strand) that would remove the uracil or the abasic site and create mismatches at nearby A/T bases because this enzyme is inherently more mutagenic at copying Ts. Along this line, specific modifications of AID in hypermutating B cells might also actively recruit UNG at the site of the lesion (31), driving the G/C mutagenesis to proceed differently from a strict saturation of the normal repair of uracils. In such a scheme, the dichotomy between translesion bypass and error-prone repair for the G/C versus A/T mutation pathways might have to be reassessed.

The absence of phenotype of the pol $\mu$  mutation of the 129/Ola mouse strain obviously questions the relevance of the pol $\mu$ -dependent mutagenic process that we described in the BL2 Burkitt's lymphoma cell line (20). In fact, it has been reported that such a pol $\mu$ -dependent mutagenesis can be induced at the Ig locus in B cell lines infected by the hepatitis C virus (32). These mutations would be related to the specific metabolic alterations brought upon infection by this oncogenic virus, alterations that may be shared by many B cell lymphomas (33). Alternatively, inactivation of pol $\mu$  in the 129/Ola mouse strain might show leakiness, in particular in activated B cells, by either read-through of the stop codon or alternative splicing. A classical inactivation of the *Pol $\mu$*  gene and the analysis of mice cumulating several deficiencies in the activities involved in hypermutation might contribute to address these issues.

## MATERIALS AND METHODS

**Construction of targeting vectors.** Three fragments from the POLH locus were amplified and cloned in the pFlox vector (34): fragment 1, 5'

flank; fragment 2, exon 4; and fragment 3, 3' flank. Construction of the targeting vector and screening of recombinant clones are described in supplemental Materials and methods (available at <http://www.jem.org/cgi/content/full/jem.20050292/DC1>). Transfection of E14.1 ES cells was performed as described (35). One recombinant clone was obtained out of 287 ES clones, and subjected to Cre-mediated excision to generate exon 4-deleted clones.

**Analysis of gene-targeted mice.** Screening of gene targeted mice was performed by PCR around exon 4 (described in Fig. 1) using the following primers: 5'-screen, 5'-GTCTCCCCAGATGTATCTCC-3', and 3'-screen, 5'-GCATTGTACACCTGTGGTCC-3' (45 s at 94°C, 30 s at 59°C, 3 min at 72°C, 40 cycles with Taq polymerase; Biolabs). The pol $\mu$  mutation of the 129/Ola background was screened by direct sequencing of a 540-bp genomic fragment encompassing exon 2 (amplified by *iota*-exon 2-5', 5'-TTA-AAGCAGGACTGAAGACC-3'; *iota*-exon 2-3', 5'-CACATTTACTC-TCGGTTGCA-3', for 15 s at 98°C, 30 s at 60°C, 15 s at 72°C, 40 cycles with Phusion DNA polymerase; Finnzymes). Pol $\eta$  mRNA expression was analyzed by RT-PCR (Stratascript; Stratagene), using splenic RNA extracted by the QIAGEN RNeasy kit and PCR primers located in exons 2 and 6 (exon 2, 5'-GGGCAGAATCGAGTGGTTGC-3'; exon 6 reverse, 5'-GCGGTTGGGCTTATTTAGTCC-3', 30 s at 95°C, 90 s at 68°C, 40 cycles with Advantage II polymerase mix; CLONTECH Laboratories, Inc.).

**Analysis of mutations in the Ig locus.** B220<sup>+</sup> PNA<sup>high</sup> B cells from Peyer's patches were isolated from 3–4-mo-old animals as described previously (8). Amplification of the J<sub>H</sub>4 intronic sequence flanking rearranged V<sub>H</sub> genes was performed using a mixture of primers amplifying most V<sub>H</sub> gene families described (compiled from the mouse V gene IMGT database, <http://imgt.cines.fr>): V1-FR3, 5'-GAGGACTCTGCRGTCTATTWCTGTGC-3'; V5-FR3, 5'-GAGGACACRGCCATGTATTACTGTGC-3'; V3-FR3, 5'-GAGGACACACCCACATATTACTGTGC-3'; V7-FR3, 5'-GAGGACAGTGCCACTTATTACTGTGC-3'; and V9-FR3, 5'-ATGAGGACATGGCTACATATTTCTGT-3', respectively, in a 6:3:1:1:1 ratio, and J<sub>H</sub>3', 5'-TGAGACCGAGGCTAGATGCC-3'. PCR was performed on five aliquots of 500 or 1,000 cells (15 s 98°C, 30 s 64°C, 30 s 72°C for 50 cycles using Phusion DNA polymerase) and 480 bp sequences were determined using the J<sub>H</sub>3' primer. A 735-bp fragment upstream from the S $\mu$  core repeat sequence was amplified using primers S $\mu$ -5', 5'-GTTGAGGTACTGATGCTGTC-3' and S $\mu$ -3', 5'-CCAGCCTAGTTTAGCTTAGC-3' (45 s at 94°C, 30 s at 58°C, 2 min at 72°C, 40 cycles with Pfu Turbo), and a 560-bp sequence was determined using primer 5'-CTATTCTGGCTCTTCT-TAAGC-3'. Sequences were obtained with an ABI Prism 3100 Genetic Analyzer after cloning in the Zero Blunt vector (Invitrogen).

**Online supplemental material.** Construction of the targeting vector for inactivation of the *Polh* gene, as well as conditions for analysis of the recombinant ES clones are described online. Online supplemental material is available at <http://www.jem.org/cgi/content/full/jem.20050292/DC1>.

We thank J. Mègret for performing cell sorting, and the Service d'Expérimentation Animale et de Transgénése (Villejuif, France) for the generation and handling of gene targeted animals.

This work was supported by a grant from the Ministère de la Recherche (A.C.I. Biologie du Développement et Physiologie Intégrative), the Ligue Nationale contre le Cancer (Equipe Labellisée), and the Fondation Princesse Grace de Monaco.

The authors have no conflicting financial interests.

Submitted: 7 February 2005

Accepted: 7 March 2005

## REFERENCES

1. Muramatsu, M., K. Kinoshita, S. Fagarasan, S. Yamada, Y. Shinkai, and T. Honjo. 2000. Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme. *Cell*. 102:553–563.

2. Barreto, V.M., A.R. Ramiro, and M.C. Nussenzweig. 2005. Activation-induced deaminase: controversies and open questions. *Trends Immunol.* 26:90–96.
3. Yoshikawa, K., I.M. Okazaki, T. Eto, K. Kinoshita, M. Muramatsu, H. Nagaoka, and T. Honjo. 2002. AID enzyme-induced hypermutation in an actively transcribed gene in fibroblasts. *Science.* 296:2033–2036.
4. Reynaud, C.-A., S. Aoufouchi, A. Faili, and J.-C. Weill. 2003. What role for AID: mutator, or assembler of the immunoglobulin mutasome? *Nat. Immunol.* 4:631–638.
5. Rada, C., J.M. Di Noia, and M.S. Neuberger. 2004. Mismatch recognition and uracil excision provide complementary paths to both Ig switching and the A/T focused phase of somatic mutation. *Mol. Cell.* 16:163–171.
6. Rada, C., G.T. Williams, H. Nilsen, D.E. Barnes, T. Lindahl, and M.S. Neuberger. 2002. Immunoglobulin isotype switching is inhibited and somatic hypermutation perturbed in UNG-deficient mice. *Curr. Biol.* 12:1748–1755.
7. Rada, C., M.R. Ehrenstein, M.S. Neuberger, and C. Milstein. 1998. Hot spot focusing of somatic hypermutation in MSH2-deficient mice suggests two stages of mutational targeting. *Immunity.* 9:135–141.
8. Frey, S., B. Bertocci, F. Delbos, L. Quint, J.C. Weill, and C.A. Reynaud. 1998. Mismatch repair deficiency interferes with the accumulation of mutations in chronically stimulated B cells and not with the hypermutation process. *Immunity.* 9:127–134.
9. Phung, Q.H., D.B. Winter, A. Cranston, R.E. Tarone, V.A. Bohr, R. Fishel, and P.J. Gearhart. 1998. Increased hypermutation at G and C nucleotides in immunoglobulin variable genes from mice deficient in the MSH2 mismatch repair protein. *J. Exp. Med.* 187:1745–1751.
10. Wiesendanger, M., B. Kneitz, W. Edelmann, and M.D. Scharff. 2000. Somatic hypermutation in MutS homologue (MSH)3<sup>-</sup>, MSH6<sup>-</sup>, and MSH3/MSH6-deficient mice reveals a role for the MSH2-MSH6 heterodimer in modulating the base substitution pattern. *J. Exp. Med.* 191:579–584.
11. Martin, A., Z. Li, D.P. Lin, P.D. Bardwell, M.D. Iglesias-Ussel, W. Edelman, and M.D. Scharff. 2003. Msh2 ATPase activity is essential for somatic hypermutation at A-T base pairs and for efficient class switching. *J. Exp. Med.* 198:1171–1178.
12. Bardwell, P.D., C.J. Woo, K. Wei, Z. Li, A. Martin, S.Z. Sack, T. Parris, W. Edelman, and M.D. Scharff. 2004. Altered somatic hypermutation and reduced class-switch recombination in exonuclease 1-mutant mice. *Nat. Immunol.* 5:224–229.
13. Martomo, S.A., W.W. Yang, and P.J. Gearhart. 2004. A role for Msh6 but not Msh3 in somatic hypermutation and class switch recombination. *J. Exp. Med.* 200:61–68.
14. Kunkel, T.A., Y.I. Pavlov, and K. Bebenek. 2003. Functions of human DNA polymerases eta, kappa and iota suggested by their properties, including fidelity with undamaged DNA templates. *DNA Repair (Amst.)* 2:135–149.
15. Masutani, C., R. Kusumoto, A. Yamada, N. Dohmae, M. Yokoi, M. Yuasa, M. Araki, S. Iwai, K. Takio, and F. Hanaoka. 1999. The XPV (xeroderma pigmentosum variant) gene encodes human DNA polymerase eta. *Nature.* 399:700–704.
16. Zeng, X., D.B. Winter, C. Kasmer, K.H. Kraemer, A.R. Lehmann, and P.J. Gearhart. 2001. DNA polymerase eta is an A-T mutator in somatic hypermutation of immunoglobulin variable genes. *Nat. Immunol.* 2:537–541.
17. Faili, A., S. Aoufouchi, S. Weller, F. Vuillier, A. Stary, A. Sarasin, C.A. Reynaud, and J.C. Weill. 2004. DNA polymerase epsilon is involved in hypermutation occurring during immunoglobulin class switch recombination. *J. Exp. Med.* 199:265–270.
18. Zeng, X., G.A. Negrete, C. Kasmer, W.W. Yang, and P.J. Gearhart. 2004. Absence of DNA polymerase epsilon reveals targeting of C mutations on the nontranscribed strand in immunoglobulin switch regions. *J. Exp. Med.* 199:917–924.
19. Kannouche, P., A.R. Fernandez de Henestrosa, B. Coull, A.E. Vidal, C. Gray, D. Zicha, R. Woodgate, and A.R. Lehmann. 2002. Localization of DNA polymerases eta and iota to the replication machinery is tightly co-ordinated in human cells. *EMBO J.* 21:6246–6256.
20. Faili, A., S. Aoufouchi, E. Flatter, Q. Guéranger, C.-A. Reynaud, and J.-C. Weill. 2002. Induction of somatic hypermutation in immunoglobulin genes is dependent on DNA polymerase iota. *Nature.* 419:944–947.
21. McDonald, J.P., E.G. Frank, B.S. Plosky, I.B. Rogozin, C. Masutani, F. Hanaoka, R. Woodgate, and P.J. Gearhart. 2003. 129-derived strains of mice are deficient in DNA polymerase iota and have normal immunoglobulin hypermutation. *J. Exp. Med.* 198:635–643.
22. Diaz, M., L.K. Verkoczy, M.F. Flajnik, and N.R. Klinman. 2001. Decreased frequency of somatic hypermutation and impaired affinity maturation but intact germinal center formation in mice expressing antisense RNA to DNA polymerase zeta. *J. Immunol.* 167:327–335.
23. Zan, H., A. Komori, Z. Li, A. Cerutti, A. Schaffer, M.F. Flajnik, M. Diaz, and P. Casali. 2001. The translesion DNA polymerase zeta plays a major role in Ig and bcl-6 somatic hypermutation. *Immunity.* 14:643–653.
24. Kondratick, C.M., M.T. Washington, S. Prakash, and L. Prakash. 2001. Acidic residues critical for the activity and biological function of yeast DNA polymerase eta. *Mol. Cell. Biol.* 21:2018–2025.
25. Kannouche, P., and A. Stary. 2003. Xeroderma pigmentosum variant and error-prone DNA polymerases. *Biochimie.* 85:1123–1132.
26. Ohmori, and T.A. Kunkel. 2000. Fidelity and processivity of DNA synthesis by DNA polymerase kappa, the product of the human DINB1 gene. *J. Biol. Chem.* 275:39678–3984.
27. Zhang, Y., F. Yuan, H. Xin, X. Wu, D.K. Rajpal, D. Yang, and Z. Wang. 2000. Human DNA polymerase kappa synthesizes DNA with extraordinarily low fidelity. *Nucleic Acids Res.* 28:4147–4156.
28. Schenten, D., V.L. Gerlach, C. Guo, S. Velasco-Miguel, C.L. Hladik, C.L. White, E.C. Friedberg, K. Rajewsky, and G. Esposito. 2002. DNA polymerase kappa deficiency does not affect somatic hypermutation in mice. *Eur. J. Immunol.* 32:3152–3160.
29. Zhang, Y., X. Wu, F. Yuan, Z. Xie, and Z. Wang. 2001. Highly frequent frameshift synthesis by human DNA polymerase mu. *Mol. Cell. Biol.* 21:7995–8006.
30. Simpson, L.J., and J.E. Sale. 2003. Rev1 is essential for DNA damage tolerance and non-templated immunoglobulin gene mutation in a vertebrate cell line. *EMBO J.* 22:1654–1664.
31. Chaudhuri, J., C. Khuong, and F.W. Alt. 2004. Replication protein A interacts with AID to promote deamination of somatic hypermutation targets. *Nature.* 430:992–998.
32. Machida, K., K.T. Cheng, V.M. Sung, S. Shimodaira, K.L. Lindsay, A.M. Levine, M.Y. Lai, and M.M. Lai. 2004. Hepatitis C virus induces a mutator phenotype: enhanced mutations of immunoglobulin and protooncogenes. *Proc. Natl. Acad. Sci. USA.* 101:4262–4267.
33. Machida, K., K.T. Cheng, V.M. Sung, K.J. Lee, A.M. Levine, and M.M. Lai. 2004. Hepatitis C virus infection activates the immunologic (type II) isoform of nitric oxide synthase and thereby enhances DNA damage and mutations of cellular genes. *J. Virol.* 78:8835–8843.
34. Gu, H., J.D. Marth, P.C. Orban, H. Mossmann, and K. Rajewsky. 1994. Deletion of a DNA polymerase beta gene segment in T cells using cell type-specific gene targeting. *Science.* 265:103–106.
35. Torres, R., and R. Kühn. 1997. Laboratory Protocols for Conditional Gene Targeting. Oxford University Press, Oxford, UK. 167 pp.
36. Bertocci, B., A. De Smet, E. Flatter, A. Dahan, J.C. Bories, C. Landreau, J.C. Weill, and C.A. Reynaud. 2002. DNA polymerases mu and lambda are dispensable for Ig gene hypermutation. *J. Immunol.* 168:3702–3706.